Biomarin Pharmaceutical Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Biomarin Pharmaceutical Stock Summary

Biomarin Pharmaceutical competes with Alnylam Pharmaceuticals, Exelixis, Halozyme Therapeutics, Arrowhead Pharmaceuticals, and Incyte. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company was incorporated in 1996 and is headquartered in San Rafael, California. Biomarin Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3045 people.

Biomarin Pharmaceutical Key Financial Ratios

Biomarin Pharmaceutical Key Balance Sheet Accounts

Biomarin Pharmaceutical Key Income Statement Accounts

Biomarin Pharmaceutical Key Cash Accounts

Biomarin Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biomarin Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Biomarin Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biomarin Pharmaceutical competition to find correlations between indicators driving Biomarin Pharmaceutical's intrinsic value. More Info.Biomarin Pharmaceutical is rated fifth in return on equity category among its peers. It is rated fourth in return on asset category among its peers reporting about  0.48  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biomarin Pharmaceutical is roughly  2.08 . At this time, Biomarin Pharmaceutical's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biomarin Pharmaceutical's earnings, one of the primary drivers of an investment's value.

Biomarin Pharmaceutical's Earnings Breakdown by Geography

Biomarin Pharmaceutical Systematic Risk

Today, most investors in Biomarin Pharmaceutical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biomarin Pharmaceutical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biomarin Pharmaceutical growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Biomarin Pharmaceutical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biomarin Pharmaceutical. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biomarin Pharmaceutical based on widely used predictive technical indicators. In general, we focus on analyzing Biomarin Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biomarin Pharmaceutical's daily price indicators and compare them against related drivers.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.